Printer Friendly

Mylan unveils generic Fortamet tablets in the US type 2 diabetes market.

M2 PHARMA-October 3, 2016-Mylan unveils generic Fortamet tablets in the US type 2 diabetes market

(C)2016 M2 COMMUNICATIONS

Pharmaceutical company Mylan NV (Nasdaq:MYL)(TASE:MYL) reported on Friday the market launch of Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg in the US.

The company said the Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg, is the generic version of Watson's Fortamet.

Following the approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride, the product is now indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

For the 12 months ending 31 July 2016, the company s Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg, had US sales of about USD770.3m, according to IMS Health.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 3, 2016
Words:155
Previous Article:Allergan plc to obtain worldwide rights to MEDI2070 from AstraZeneca.
Next Article:CTI BioPharma reports departure of president & CEO James A. Bianco.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters